Autologous bone graft: when shall we add growth factors?
Although the unquestionable value of autologous bone grafting and the analogous value of the reaming by-products in nonunion treatment have been mentioned extensively in the literature, there is ongoing vivid discussion for the treatment of those case scenarios where the fracture nonunion is complicated by other local environment adverse circumstances. The graft expansion with growth factors as the bone morphogenetic proteins (BMPs) offers the possibility to reduce the number of operative procedures, complications, length of hospital stay, and time to union. In this article, we consider the potential clinical scenarios for graft expansion with BMPs.
Giannoudis
Peter V
PV
Department of Trauma & Orthopedic Surgery, University of Leeds, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK. pgiannoudi@aol.com
Dinopoulos
Haralampos T
HT
D000818:Animals; D016025:Bone Transplantation / Q000379:methods*; D017102:Fracture Healing / Q000187:drug effects*; D005599:Fractures, Ununited / Q000188:drug therapy / Q000601:surgery*; D006085:Graft Survival / Q000187:drug effects; D013006:Growth Hormone / Q000494:pharmacology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology*; D013997:Time Factors; D014182:Transplantation, Autologous
D036341:Intercellular Signaling Peptides and Proteins; D013006:Growth Hormone